Latest News of XRX
Is Xerox Holdings Corporation (XRX) an Oversold NASDAQ Stock to Invest In Now?
By Yahoo! Finance |
2 weeks ago
A list of 10 oversold NASDAQ stocks for investment was compiled. The NASDAQ hit a record high, driven by tech stocks. Analyst Nick Colas shared insights on market trends, predicting continued growth d...
Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock
By Yahoo! Finance |
2 months ago
A list of top AI stocks by BlackRock includes Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Despite market volatility, BlackRock advises diversifying investments into sectors benefiting from AI infra...
Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers
By Yahoo! Finance |
2 months ago
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a mid-sized biotech company in pre-commercial stages, focusing on developing treatments for various ailments. It partners with AI drug discovery firm E...
-
Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?
By Yahoo! Finance | 2 months agoAn article lists the top multibagger penny stocks of 2025, including Lexicon Pharmaceuticals, analyzing its potential. Multibagger stocks can yield significant returns but are risky. Market trends sug...
-
Xerox Holdings Corporation (XRX): AR Ambitions Overshadowed By Financial Struggles and Short Seller Pressure
By Yahoo! Finance | 2 months agoXerox Holdings Corporation (NYSE:XRX) is ranked 8th on the list of AR stocks short sellers do not recommend. Despite potential, financial struggles and reduced revenue make it an unattractive investme...
-
Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies
By Yahoo! Finance | 2 months agoRecursion Pharmaceuticals Inc. is a leading biotech company utilizing AI for drug discovery, attracting investments and partnerships. Despite its growth potential, it ranks 6th among the best medical ...
-
Xerox Holdings (NASDAQ:XRX) Has Announced A Dividend Of $0.25
By Yahoo! Finance | 3 months agoXerox Holdings Corporation is set to pay investors $0.25 per share with a 9.8% dividend yield, above the industry average. Although not profitable, the company's cash flow sustains dividends....
-
Xerox Holdings Corporation (XRX): The Best High Yield Dividend Stock With Upside Potential?
By Yahoo! Finance | 4 months agoThe article discusses the performance of high-yield dividend stocks and their benefits during various market conditions. It highlights Xerox Holdings Corporation as a high-yield dividend stock with po...
-
Xerox Holdings Corporation (XRX) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 4 months agoXerox Holdings Corporation is a workplace technology company that offers hardware, services, and software globally. The company operates through Print and Other, and FITTLE segments, providing documen...
-
Xerox Holdings Corporation (XRX) Stock Forecasts
By Yahoo! Finance | 4 months agoXerox is an OEM and software company specializing in printing technology and solutions. They focus on multifunction printers for large enterprises and offer services like managed print services. The c...
-
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)
By Yahoo! Finance | 4 months agoRecursion Pharmaceuticals Inc utilizes AI to speed up drug discovery. Blake Borgeson sold 350,970 shares, part of a trend with 73 insider sells and no buys. With a market cap of $1.80 billion, the sto...
-
Xerox Holdings (NASDAQ:XRX) Has Affirmed Its Dividend Of $0.25
By Yahoo! Finance | 5 months agoXerox Holdings Corporation will pay a dividend of $0.25 per share on July 31, with a yield of 7.3%. Despite declining earnings per share, the company's stable dividend history raises investor confiden...
-
Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69%
By Yahoo! Finance | 5 months agoLong term investing can be profitable, but not always immune to losses. For instance, Lexicon Pharmaceuticals' stock has declined significantly over five years, indicating high risk due to low revenue...